Translational Session
Glomerular Disease Following Kidney Transplantation: Cutting-Edge Therapeutic Approaches
October 26, 2024 | 02:00 PM - 04:00 PM
Location: Ballroom 20B/C, Convention Center
Session Description
Glomerular disease is a leading cause of graft loss following kidney transplant, with de novo disease and recurrent glomerulonephritis contributing nearly equally to poor outcomes. This session reviews RCTs in native CKD using novel therapeutic agents for the treatment of glomerular disease and translates these approaches to the transplant setting. Our current understanding of transplant glomerular injury (transplant glomerulopathy) is reviewed and implications for clinical trial design and the potential for individualized therapeutic management are highlighted.
ASN thanks the European Renal Association (ERA) and ERA Ambassador, Dr. Olivier Aubert.
Learning Objective(s)
- Discuss novel therapeutic interventions for recurrent FSGS following kidney transplant
- Describe novel therapies for atypical hemolytic uremic syndrome and C3 glomerulonephritis from the CKD setting to the transplant setting
- Compare and contrast nephroprotective strategies for diabetic kidney disease in people with CKD and in transplant populations
- Summarize molecular phenotypes of transplant glomerulopathy and treatment implications
Learning Pathway(s)
- Kidney Transplantation
- Glomerular Diseases
Moderators
Presentations
- Current and Novel Approaches to the Treatment of Recurrent FSGS after Transplant
02:00 PM - 02:30 PM
- Clinical Approaches for the Prevention and Treatment of Recurrent Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy
02:30 PM - 03:00 PM
- Prevention of Diabetic Nephropathy after Kidney Transplant: State-of-the-Art Care Considerations
03:00 PM - 03:30 PM
- Understanding Transplant Glomerulopathy beyond Histology: Implications for Intervention
03:30 PM - 04:00 PM